Chinese companies lead ADC development pipeline: GlobalData
A significant level of increase is seen in Chinese companies within the Antibody-drug conjugates market.
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
antibody-drug conjugates
Enzene Biosciences inaugurates R&D Center with open lab setup in Pune
The new R&D centre signals strategic growth plans, expanded capabilities and enhanced services
Daiichi Sankyo will remain dominant in ADC market for oncology treatments: GlobalData
By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion
Antibody-drug conjugates gain traction in China oncology market: GlobalData
The diagnosed prevalent cases of gastric, breast, and bladder cancers in China are expected to increase at a CAGR of 2.6 per cent,…
Sanofi and Seagen announce collaboration to develop and commercialise multiple novel antibody-drug…
The companies jointly fund and develop up to three antibody-drug conjugate programmes for the treatment of cancer
Drug developers take fresh aim at ‘guided-missile’ cancer drugs
These antibody-drug conjugates, or ADCs, from companies including AztraZeneca and GlaxoSmithKline, are described by researchers as…